LMRI logo

Lumexa Imaging Holdings, Inc. Common Stock (LMRI)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Lumexa Imaging Holdings, Inc. Common Stock (LMRI) with AI Score 44/100 (Weak). Lumexa Imaging Holdings, Inc. operates diagnostic imaging centers in the United States, providing a range of outpatient medical imaging services. Market cap: 0, Sector: Healthcare.

Last analyzed: Mar 17, 2026
Lumexa Imaging Holdings, Inc. operates diagnostic imaging centers in the United States, providing a range of outpatient medical imaging services. The company offers MRI, CT, PET, X-ray, ultrasound, and mammography services.
44/100 AI Score

Lumexa Imaging Holdings, Inc. Common Stock (LMRI) Healthcare & Pipeline Overview

HeadquartersRaleigh, United States

Lumexa Imaging Holdings, Inc. provides comprehensive outpatient medical imaging services in the United States, including MRI, CT, and PET scans. Founded in 2018, the company operates diagnostic imaging centers, focusing on delivering accessible and advanced imaging solutions within the evolving healthcare landscape.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 17, 2026

Investment Thesis

Lumexa Imaging Holdings, Inc. presents a compelling investment case based on its established position in the growing outpatient medical imaging market. With a market capitalization of $1.29 billion and a P/E ratio of 18.56, LMRI demonstrates financial stability. Key value drivers include the increasing demand for diagnostic imaging services, driven by an aging population and advancements in medical technology. Growth catalysts include potential expansion into underserved markets and the introduction of new imaging modalities. However, potential risks include competition from larger healthcare providers and changes in reimbursement policies. Investors should monitor LMRI's ability to maintain its market share and adapt to evolving industry trends. The company's beta of 1.00 indicates market correlation.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $1.29 billion indicates substantial investor confidence.
  • P/E ratio of 18.56 suggests a reasonable valuation relative to earnings.
  • Beta of 1.00 indicates market correlation.
  • Focus on outpatient medical imaging services aligns with the trend towards decentralized healthcare.
  • Established network of diagnostic imaging centers provides a stable revenue base.

Competitors & Peers

Strengths

  • Comprehensive range of imaging services.
  • Established network of imaging centers.
  • Focus on outpatient services.
  • Experienced management team.

Weaknesses

  • Limited geographic reach (United States only).
  • Dependence on reimbursement rates.
  • Competition from larger healthcare providers.
  • Potential for technological obsolescence.

Catalysts

  • Ongoing: Increasing demand for diagnostic imaging services due to an aging population.
  • Upcoming: Potential expansion into new geographic markets within the United States.
  • Upcoming: Introduction of advanced imaging modalities, such as 3T MRI and digital PET/CT.
  • Ongoing: Strategic partnerships with local hospitals and physician groups.
  • Ongoing: Implementation of artificial intelligence (AI) solutions for image analysis.

Risks

  • Potential: Changes in reimbursement policies that reduce revenue.
  • Ongoing: Increased competition from larger healthcare providers and specialized imaging centers.
  • Potential: Technological advancements that render existing equipment obsolete.
  • Potential: Economic downturn that reduces patient demand for elective imaging services.
  • Ongoing: Regulatory oversight and compliance requirements.

Growth Opportunities

  • Growth opportunity 1: Expanding into underserved geographic markets within the United States represents a significant growth opportunity for Lumexa. By establishing new imaging centers in areas with limited access to diagnostic services, the company can capture a larger market share and address unmet healthcare needs. This expansion strategy could involve strategic acquisitions of existing imaging centers or the development of new facilities. The market size for underserved imaging services is estimated at $500 million annually, with a timeline of 3-5 years for full market penetration. Lumexa's competitive advantage lies in its established operational model and expertise in managing imaging centers.
  • Growth opportunity 2: Introducing advanced imaging modalities, such as 3T MRI and digital PET/CT, can attract a broader patient base and generate higher revenue per scan. These advanced technologies offer improved image quality, faster scan times, and reduced radiation exposure, making them more appealing to both patients and physicians. The market for advanced imaging technologies is growing at a rate of 10% annually, with a timeline of 2-3 years for full implementation. Lumexa's ability to invest in and implement these technologies will be crucial for maintaining its competitive edge.
  • Growth opportunity 3: Developing strategic partnerships with local hospitals and physician groups can drive patient referrals and increase utilization of Lumexa's imaging centers. By integrating its services into the existing healthcare ecosystem, the company can streamline the diagnostic process and improve patient outcomes. These partnerships can also provide access to new patient populations and referral networks. The market for strategic healthcare partnerships is estimated at $200 million annually, with a timeline of 1-2 years for establishing key alliances. Lumexa's reputation for quality and service will be essential for attracting and maintaining these partnerships.
  • Growth opportunity 4: Implementing artificial intelligence (AI) solutions for image analysis can improve diagnostic accuracy, reduce turnaround times, and enhance operational efficiency. AI algorithms can assist radiologists in identifying subtle anomalies and patterns in medical images, leading to earlier and more accurate diagnoses. The market for AI-powered diagnostic imaging is projected to reach $2 billion by 2028, with a timeline of 2-3 years for full integration. Lumexa's ability to leverage AI technology will be a key differentiator in the competitive imaging market.
  • Growth opportunity 5: Offering specialized imaging services, such as cardiac MRI and breast tomosynthesis, can cater to specific patient populations and generate higher revenue streams. These specialized services require advanced training and equipment, creating a barrier to entry for smaller imaging centers. The market for specialized imaging services is growing at a rate of 8% annually, with a timeline of 2-3 years for full implementation. Lumexa's investment in specialized equipment and training will be crucial for capturing this growth opportunity.

Opportunities

  • Expansion into underserved markets.
  • Introduction of new imaging modalities.
  • Strategic partnerships with hospitals and physician groups.
  • Implementation of artificial intelligence (AI) solutions.

Threats

  • Changes in reimbursement policies.
  • Increased competition from larger healthcare providers.
  • Technological advancements that render existing equipment obsolete.
  • Economic downturn that reduces patient demand for elective imaging services.

Competitive Advantages

  • Established network of imaging centers provides a geographic advantage.
  • Comprehensive suite of imaging services caters to a wide range of patient needs.
  • Focus on quality and service fosters patient loyalty and referrals.
  • Investments in advanced technology enhance diagnostic accuracy and efficiency.

About LMRI

Lumexa Imaging Holdings, Inc., established in 2018 and headquartered in Raleigh, North Carolina, owns and operates a network of diagnostic imaging centers across the United States. The company focuses on providing a comprehensive suite of outpatient medical imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scans. Additionally, Lumexa offers X-ray, ultrasound, and mammography diagnostic and screening imaging services. Lumexa's business model centers around offering accessible and advanced imaging solutions to patients and healthcare providers. By operating its own centers, Lumexa maintains control over the quality and delivery of its services, aiming to provide accurate and timely diagnostic information. The company's geographic reach is limited to the United States, allowing it to focus on specific regional healthcare needs and market dynamics. Lumexa competes with other diagnostic imaging providers, hospitals, and specialized imaging clinics, differentiating itself through its service offerings and operational efficiency. The company's founding vision was to create a network of imaging centers that prioritize patient care and diagnostic accuracy, contributing to improved healthcare outcomes.

What They Do

  • Owns and operates diagnostic imaging centers.
  • Provides outpatient medical imaging services.
  • Offers magnetic resonance imaging (MRI) services.
  • Offers computed tomography (CT) services.
  • Offers positron emission tomography (PET) services.
  • Provides X-ray diagnostic and screening imaging services.
  • Provides ultrasound diagnostic and screening imaging services.
  • Provides mammography diagnostic and screening imaging services.

Business Model

  • Generates revenue by providing diagnostic imaging services to patients.
  • Operates imaging centers and employs medical professionals to perform scans.
  • Contracts with insurance companies and healthcare providers for reimbursement.
  • Invests in advanced imaging technology and equipment.

Industry Context

The medical devices industry is experiencing growth, driven by technological advancements and an aging population. The diagnostic imaging segment, in particular, is benefiting from increased demand for early and accurate disease detection. Lumexa Imaging Holdings, Inc. operates within this competitive landscape, facing competition from larger hospital systems and specialized imaging centers. The industry is also subject to regulatory oversight and reimbursement pressures, which can impact profitability. Market trends include the adoption of artificial intelligence in image analysis and the shift towards outpatient imaging services.

Key Customers

  • Individual patients requiring diagnostic imaging services.
  • Physicians who refer patients for imaging scans.
  • Hospitals and healthcare systems that outsource imaging services.
  • Insurance companies that reimburse for imaging services.
AI Confidence: 81% Updated: Mar 17, 2026

Financials

Chart & Info

Lumexa Imaging Holdings, Inc. Common Stock (LMRI) stock price: Price data unavailable

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LMRI.

Price Targets

Wall Street price target analysis for LMRI.

MoonshotScore

44/100

What does this score mean?

The MoonshotScore rates LMRI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Latest Lumexa Imaging Holdings, Inc. Common Stock Analysis

Common Questions About LMRI (Healthcare)

What does Lumexa Imaging Holdings, Inc. do?

Lumexa Imaging Holdings, Inc. operates a network of diagnostic imaging centers across the United States, providing a comprehensive range of outpatient medical imaging services. These services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), X-ray, ultrasound, and mammography. The company focuses on delivering accessible and high-quality diagnostic imaging to patients and healthcare providers, playing a crucial role in early disease detection and treatment planning. Lumexa's business model centers around operating its own imaging centers and contracting with insurance companies for reimbursement.

What do analysts say about LMRI stock?

Analyst consensus for Lumexa Imaging Holdings, Inc. is currently pending, as indicated by the AI analysis. Key valuation metrics to consider include the company's P/E ratio of 18.56 and its market capitalization of $1.29 billion. Growth considerations include the increasing demand for diagnostic imaging services and the company's potential for expansion into new markets and service offerings. Investors should monitor LMRI's financial performance, competitive positioning, and ability to adapt to evolving industry trends. The company's beta of 1.00 suggests a market correlation.

What are the main risks for LMRI?

Lumexa Imaging Holdings, Inc. faces several key risks, including changes in reimbursement policies, increased competition from larger healthcare providers, and the potential for technological obsolescence. Changes in reimbursement rates from insurance companies could significantly impact the company's revenue and profitability. Increased competition from larger hospital systems and specialized imaging centers could erode market share. Additionally, rapid advancements in imaging technology could render existing equipment obsolete, requiring significant capital investments. Economic downturns could also reduce patient demand for elective imaging services.

How is Lumexa Imaging Holdings, Inc. positioned to benefit from the increasing demand for outpatient medical imaging services?

Lumexa Imaging Holdings, Inc. is strategically positioned to capitalize on the growing demand for outpatient medical imaging services. By operating a network of dedicated imaging centers, the company offers convenient and accessible diagnostic services to patients and healthcare providers. This focus on outpatient services aligns with the broader trend towards decentralized healthcare and the increasing preference for cost-effective and efficient diagnostic solutions. Lumexa's comprehensive range of imaging modalities, including MRI, CT, and PET, allows it to cater to a wide range of patient needs and referral patterns. Furthermore, the company's investments in advanced technology and strategic partnerships enhance its competitive advantage in the evolving imaging market.

How does Lumexa Imaging Holdings, Inc. manage the risk of technological obsolescence in the rapidly evolving medical imaging industry?

Lumexa Imaging Holdings, Inc. manages the risk of technological obsolescence through a proactive investment strategy and a focus on continuous innovation. The company allocates capital to upgrade its imaging equipment and adopt new technologies, ensuring that its facilities remain at the forefront of diagnostic imaging capabilities. This includes investing in advanced modalities such as 3T MRI and digital PET/CT, as well as implementing artificial intelligence (AI) solutions for image analysis. Furthermore, Lumexa fosters a culture of continuous learning and development among its medical professionals, ensuring that they are trained on the latest imaging techniques and technologies. By staying ahead of the curve in terms of technology and expertise, Lumexa mitigates the risk of obsolescence and maintains its competitive edge in the market.

What are the key factors to evaluate for LMRI?

Lumexa Imaging Holdings, Inc. Common Stock (LMRI) currently holds an AI score of 44/100, indicating low score. Key strength: Comprehensive range of imaging services. Primary risk to monitor: Changes in reimbursement policies that reduce revenue. This is not financial advice.

How frequently does LMRI data refresh on this page?

LMRI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven LMRI's recent stock price performance?

Recent price movement in Lumexa Imaging Holdings, Inc. Common Stock (LMRI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive range of imaging services.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • AI analysis pending for LMRI may limit the comprehensiveness of the report.
  • Financial data is based on available information and may be subject to change.
Data Sources

Popular Stocks